High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry

Registro completo de metadados
Autor(es): dc.creatorMarques, Claudia Diniz Lopes-
Autor(es): dc.creatorKakehasi, Adriana Maria-
Autor(es): dc.creatorPinheiro, Marcelo Medeiros-
Autor(es): dc.creatorMota, Licia Maria Henrique-
Autor(es): dc.creatorAlbuquerque, Cleandro Pires-
Autor(es): dc.creatorSilva, Carolina Rocha-
Autor(es): dc.creatorSantos, Gabriela Porfirio Jardim-
Autor(es): dc.creatorReis Neto, Edgard Torres-
Autor(es): dc.creatorMatos, Pedro-
Autor(es): dc.creatorDevide, Guilherme-
Autor(es): dc.creatorDantas, Andrea-
Autor(es): dc.creatorGiorgi, Rina Dalva-
Autor(es): dc.creatorOmura, Felipe-
Autor(es): dc.creatorMarinho, Adriana de Oliveira-
Autor(es): dc.creatorValadares, Lilian David Azevedo-
Autor(es): dc.creatorMelo, Ana Karla G.-
Autor(es): dc.creatorRibeiro, Francinne Machado-
Autor(es): dc.creatorFerreira, Gilda Aparecida-
Autor(es): dc.creatorSantos, Flavia Patricia de Sena-
Autor(es): dc.creatorRibeiro, Sandra Lucia Euzebio-
Autor(es): dc.creatorAndrade, Nicole Pamplona Bueno-
Autor(es): dc.creatorYazbek, Michel Alexandre-
Autor(es): dc.creatorSouza, Viviane Angelina de-
Autor(es): dc.creatorPaiva, Eduardo S.-
Autor(es): dc.creatorAzevedo, Valderilio Feijo-
Autor(es): dc.creatorFreitas, Ana Beatriz Santos Bacchiega de-
Autor(es): dc.creatorProvenza, José Roberto-
Autor(es): dc.creatorToledo, Ricardo Acayaba de-
Autor(es): dc.creatorFontenelle, Sheilla-
Autor(es): dc.creatorCarneiro, Sueli-
Autor(es): dc.creatorXavier, Ricardo-
Autor(es): dc.creatorPileggi, Gecilmara Cristina Salviato-
Autor(es): dc.creatorReis, Ana Paula Monteiro Gomides-
Data de aceite: dc.date.accessioned2021-10-14T17:52:07Z-
Data de disponibilização: dc.date.available2021-10-14T17:52:07Z-
Data de envio: dc.date.issued2021-03-30-
Data de envio: dc.date.issued2021-03-30-
Data de envio: dc.date.issued2020-
Fonte completa do material: dc.identifierhttps://repositorio.unb.br/handle/10482/40399-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1136/rmdopen-2020-001461-
Fonte completa do material: dc.identifierhttps://orcid.org/0000-0002-3333-2621-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/618107-
Descrição: dc.descriptionObjectives To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. Methods Analysis of the first 8 weeks of observational multicentre prospective cohort study (ReumaCoV Brasil register). Patients with IMRD and COVID-19 according to the Ministry of Health criteria were classified as eligible for the study. Results 334 participants were enrolled, a majority of them women, with a median age of 45 years; systemic lupus erythematosus (32.9%) was the most frequent IMRD. Emergency care was required in 160 patients, 33.0% were hospitalised, 15.0% were admitted to the ICU and 10.5% underwent mechanical ventilation; 28 patients (8.4%) died. In the multivariate adjustment model for emergency care, diabetes (prevalence ratio, PR 1.38; 95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) (PR 1.49; 95% CI 1.21 to 1.85; p<0.001) and pulse therapy with methylprednisolone (PR 1.38; 95% CI 1.14 to 1.67; p=0.001) remained significant; for hospitalisation, age >50 years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 1.16 to 5.45; p=0.004) and methylprednisolone pulse therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; p<0.001) and pulse therapy with methylprednisolone (PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two variables associated with death were pulse therapy with methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 1.59 to 5.14; p<0.018). Conclusions Age >50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process.-
Formato: dc.formatapplication/pdf-
Publicador: dc.publisherBMJ Journals-
Direitos: dc.rightsAcesso Aberto-
Direitos: dc.rightsOpen access - This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/ licenses/by-nc/4.0/. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.-
Palavras-chave: dc.subjectPacientes-
Palavras-chave: dc.subjectReumatismo-
Palavras-chave: dc.subjectCovid-19-
Título: dc.titleHigh levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:UNB

Não existem arquivos associados a este item.